CHEK2 and cancer: Among 640,292 individuals in Geisinger and UK Biobank who were not ascertained based on phenotype, there was a significantly increased frequency of CHEK2 germline P/LP variants among individuals with DFSP (n = 3/65 [4.6%]) compared with those without this cancer (n = 6388/640,227 [1.0%]) (Fisher exact, P = .03) (Table 2).